tbuckley/cabot-search huggingface dataset:
THU0543 Evaluation of The fibromyalgia Rapid Screening Tool (First) Questionnaire To Screen fibromyalgia Associated with Inflammatory Rheumatic Disease
Authors: A. Fan, B. Pereira, A. Tournadre, Z. Tatar, S. Malochet-Guinamand, M. Soubrier, J.-J. Dubost
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Fibromyalgia (FM) is prevalent in patients with chronic inflammatory rheumatic diseases (CIRd), where it hampers diagnosis and activity assessment. No tool for screening FM associated with CIRd has ever been evaluated. The Fibromyalgia Rapid Screening Tool (FiRST) is a brief and simple self-complete questionnaire that has been validated for screening FM in patients with diffuse chronic pain. <h3>Objectives</h3> The purpose of this study was to evaluate how well FiRST performs on screening for FM associated with CIRd. <h3>Methods</h3> This single-center cross-sectional study was conducted between September 2014 and April 2015 on all patients with chronic pain presenting for rheumatoid arthritis (RA), spondyloarthritis (SpA), and connective tissue disease (Sjögren9s syndrome (SS), systemic lupus erythematosus (SLE), scleroderma (Scl), myositis). Diagnosis of FM was based on ACR–90 classification criteria (to minimize interfering overlap between rheumatic disease-related pain and FM-related pain) and expert opinion. <h3>Results</h3> The population included 605 patients: 279 RA, 271 SpA (52 psoriatic arthritis, 126 radiographic axial SpA, 64 non-radiographic axial SpA, 29 peripheral SpA), 57 connective tissue disease. In total, 51 patients had FM meeting the ACR–90 criteria, and 93 patients were given a diagnosis of FM by the expert. When tested against the ACR–90 classification criteria, FiRST demonstrated a sensitivity of 74.5%, a specificity of 80.4%, a positive predictive value of 26.6% and a negative predictive value of 97.1%. Specificity was significantly weaker in the connective tissue disease group (RA: 84.4%, SpA: 80.2%, connective tissue disease: 59.6%; <i>p</i>&lt;0.001). When tested against expert opinion, FiRST demonstrated a sensitivity of 75.8%, a specificity of 85.1%, a positive predictive value of 48.3% and a negative predictive value of 95%. FiRST underperformed on sensitivity in the SpA group compared to the connective tissue disease group (66% <i>vs</i> 94.4%; <i>p</i>=0.004). Performances varied according to item in the self-complete questionnaire. <h3>Conclusions</h3> The FiRST self-questionnaire performs less well in inflammatory rheumatic diseases than in primary fibromyalgia, but nevertheless it remains a simple and rapid tool to help rheumatologist and general practitioner detects fibromyalgia associated with inflammatory rheumatic disease. <h3>Disclosure of Interest</h3> None declared
P1.08-048 Comparison of Pulmonary Function after Robotic-Assisted Video-Thoracoscopic Lobectomies vs Segmentectomies
Authors: Maria Echavarria, Anna Cheng, Frank Velez, Emily Ng, Carla Moodie, Joseph Garrett, Jacques-Pierre Fontaine, Eric Toloza
Journal: Journal of Thoracic Oncology (2017)
OP0148 First in Class Therapeutic Acpa Reduces Inflammation by Inhibition of Netosis
Authors: R.G. Chirivi, J.W. van Rosmalen, G. Schmets, Es H. van, J.M. Raats
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Neutrophils together with aberrant Neutrophil Extracellular Trap (NET) formation contribute to the induction and propagation of inflammation. A growing number of studies indicate that Peptidyl Arginine Deiminases (PADs) mediated conversion of arginine to citrulline residues in proteins are essential for NETosis, generation of auto-antigens, autoimmunity, and the breaking of tolerance in rheumatoid arthritis (RA). In RA patients, enhanced NETosis is observed in circulating and synovial neutrophils, and NET components are observed in blood and joints. <h3>Objectives</h3> Our objective is to develop a novel first in class NET-inhibiting therapeutic anti-citrullinated protein antibody (tACPA) treatment for RA and other auto-immune diseases in which aberrant NET formation adds to the severity of the disease. <h3>Methods</h3> Human neutrophils from blood donors have been used in order to visualize the NETosis inhibiting properties of tACPA. Furthermore, collagen antibody-induced (CAIA) as well as collagen-induced (CIA) arthritis mouse models have been used in order to test the therapeutic properties of tACPA. <h3>Results</h3> In human neutrophils, NETosis induction with calcium ionophore A-23187 or physiological stimuli like human synovial fluid is strongly inhibited by tACPA treatment (40–90% NET reduction compared to non-treated cells (n&gt;40 different donors)). This observation has been confirmed by Myeloperoxidase and Neutrophil Elastase activity as well as immunohistochemistry read-outs. In both CAIA and CIA mouse models, NET-inhibiting tACPAs are able to prevent the onset and/or exacerbation of inflammation, and prevent or strongly reduce joint damage. Histological analysis of tACPA-treated inflamed mouse joints revealed a significant decrease in neutrophil influx. We identified the epitopes recognized by tACPA to be citrullinated domains of histones 2A and 4. <h3>Conclusions</h3> We have identified antibodies directed against a citrullinated epitope in murine and human histones 2A and 4. In RA mouse models, we demonstrate that tACPAs strongly prevents the occurrence of swelling and joint damage. We propose that the therapeutic effect of tACPA acts through the inhibition of NET and auto-antigen formation, clearance of formed NETs and toxic histones. In RA patients extinguishing auto-antigen production offers an orthogonal approach for treating this destructive autoimmune disease, potentially without impacting systemic immunity. Citryll and ModiQuest are developing tACPAs as treatment for diseases where NETs and NETosis are driving or contributing to disease progression. <h3>Disclosure of Interest</h3> R. Chirivi Shareholder of: Citryll BV, Employee of: ModiQuest BV, J. van Rosmalen Employee of: ModiQuest BV, G. Schmets Employee of: ModiQuest BV, H. van Es Shareholder of: Citryll BV, Employee of: Citryll BV, J. Raats Shareholder of: Citryll BV and ModiQuest BV
Total Marrow Irradiation (TMI) with Helical Tomotherapy and PBPC Following High-Dose Melphalan and PBPC as Part of Tandem Therapy for Patients with Multiple Myeloma.
Authors: George Somlo, Stephen Forman, Leslie Poppelwell, Tim Schultheiss, Paul Frankel, Amrita Krishnan, An Liu, Firoozeh Sahebi, Parker Pablo, Jeffrey Wong
Journal: Blood (2005)
YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection
Authors: Noelia Purroy, Pau Abrisqueta, Eva Calpe, Cecilia Carpio, Carles Palacio, Laura Gallur, Marta Crespo, Francesc Bosch
Journal: Blood (2012)
Prospective Clinical Study of Surgical Resection Followed by CHOP in Localized Intestinal Lymphoma.
Authors: Jeeyun Lee, Won Seog Kim, Sung Yong Oh, Jung Mi Kwon, Hyun Jung Kim, Hyo-Rak Lee, Byeong Bae Park, Kihyun Kim, Chul W. Jung, Keunchil Park
Journal: Blood (2005)
Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification
Authors: Devaveena Dey, Jana Bagarova, Sarah J. Hatsell, Kelli A. Armstrong, Lily Huang, Joerg Ermann, Ashley J. Vonner, Yue Shen, Agustin H. Mohedas, Arthur Lee, Elisabeth M. W. Eekhoff, Annelies van Schie, Marie B. Demay, Charles Keller, Amy J. Wagers, Aris N. Economides, Paul B. Yu
Journal: Science Translational Medicine (2016)

Tissue-specific manifestations of the congenital bone-forming syndrome FOP are mediated by multiple tissue-resident stem cell populations.
Abnormalities in MUC5AC and MUC5B Protein in Airway Mucus in Asthma
Authors: Marrah E. Lachowicz-Scroggins, Shaopeng Yuan, Sheena C. Kerr, Eleanor M. Dunican, Michelle Yu, Stephen D. Carrington, John V. Fahy
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Definition of abbreviation: n/a = not available.Asthma was diagnosed by either methacholine hyperresponsiveness or bronchodilator responsiveness.*Age, body mass index, and spirometry data are presented as mean 6 SD.† Sputum cell count data is presented as the median (range).
FRI0491 Etiology and Clinical Features of Uveitis in A Tertiary Center in Turkey
Authors: D. Arslan Tas, I. Turk, N. Cuzdan Coskun, O. Kudas, S.O. Badak, E. Esen, S. Sızmaz, N. Demircan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Uveitis is inflammation of uvea (iris, ciliary body, choroid). Uveitis is classified as anatomically (anterior, intermediate, posterior, panuveitis) and etiologically (infectious, non-infectious and masquerade) (1). <h3>Objectives</h3> The aim of this study was to investigate etiology and clinical properties of uveitis in a tertiary center in Turkey. <h3>Methods</h3> Uveitis patients who admitted to our hospital from 2013 to 2015 were evaluated. Age, gender, type of uveitis, course of the attacks and etiology were noted. <h3>Results</h3> One hundred patients with uveitis (54% men, 46% women; age 40.01±14.1 years) were included in the study. The course of the disease was mostly acute (42%) followed by recurrent (36%) and chronic form (22%). Specific diagnosis was established in 68% of patients; whereas 32% of patients were evaluated as idiopathic. Etiology was spondiloartropathy (SpA) in 30%, Behçet9s disease in 16%, infectious in 13%, connective tissue disease associated in 6%, sarcoidosis in 2% and malignancy associated uveitis in 1% of the patients. 67% of the patients had unilateral and 33% of patients had bilateral uveitis. The characteristic properties of patients with SpA were as 56% men and 43% women; aged 43.57 ± 16.45 years. 60% of the patients with SpA had anterior, 40% had panuveitis. 46% of SpA patients had recurrent, 43% had acute and 10% had chronic uveitis. HLA B27 was positive in 50% of SpA patients. Sacroiliitis on MRI was detected in 76% of patients. There were 32 idiopathic uveitis patients (53.1% women). Panuveitis was the most common type (37.5%) among idiopathic uveitis patients, followed by posterior uveitis (34.4%), anterior uveitis (21.9%) and intermediate uveitis (6.2%), respectively. There were 16 patients with Behçet9s disease, 62.5% of them were men. 62.5% of patients with Behçet9s disease had panuveitis, 18.8% had anterior and 18.8% had posterior uveitis. <h3>Conclusions</h3> According to the literature posterior segment involvement is a rare presentation of SpA associated uveitis (2).The results of this study are noteworthy that higher incidence of panuveitis can be seen in SpA patients. <h3>References</h3> Deschenes J, Murray PI, Rao NA, Nussenblatt RB; International Uveitis Study Group. International Uveitis Study Group (IUSG): Clinical classification of uveitis. Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):1–2. Ali A, Samson CM. Seronegative spondyloarthropathies and the eye. Curr Opin Ophtalmol. 2007 Nov;18(6):476–80. <h3>Disclosure of Interest</h3> None declared
Genetic and Pharmacologic Targeting of STAT5/Gab2/PI3K/mTOR Signaling in a Mouse Myeloproliferative Disease Model.
Authors: Geqiang Li, Zhengqi Wang, Kristy L. Miskimen, Xiu Yan Xie, William Tse, Fabrice Gouilleux, Richard Moriggl, Kevin D. Bunting
Journal: Blood (2009)
Response to Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38: e145–e146
Authors: Saeid Shahraz, Anastassios G. Pittas, Christine M. Lundquist, Goodarz Danaei, David M. Kent
Journal: Diabetes Care (2016)

We have read with interest the study by Cahn et al. (1) that summarized the results on the salient determinants of setting glycemic targets by a large group of worldwide diabetologists. The authors showed that life expectancy and the risk of developing hypoglycemia are the two …
New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations
Authors: Elizabeth P. Harausz, Anthony J. Garcia-Prats, James A. Seddon, H. Simon Schaaf, Anneke C. Hesseling, Jay Achar, Jonathan Bernheimer, Andrea T. Cruz, Lia D’Ambrosio, Anne Detjen, Stephen M. Graham, Jennifer Hughes, Sylvie Jonckheere, Ben J. Marais, Giovanni Battista Migliori, Lindsay McKenna, Alena Skrahina, Marina Tadolini, Peyton Wilson, Jennifer Furin
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.
First-Line Rituximab Efficacy and Safety in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Experiencing a Non Optimal Response to Therapeutical Plasma Exchange: Results of a Prospective Multicenter Phase 2 Study From the French Reference Center for the Management of Thrombotic Microangiopathies.
Authors: Antoine Froissart, Marc Buffet, Agnes Veyradier, Pascale Poullin, François Provot, Sandrine Malot, Michael Schwarzinger, Lionel Galicier, Philippe Vanhille, Jean-Paul Vernant, Dominique Bordessoule, Bertrand Guidet, Elie Azoulay, Eric Rondeau, Jean-Paul Mira, Alain Wynckel, Karine Clabault, Gabriel Choukroun, Claire Presne, Jacques Pourrat, Mohamed Hamidou, Linda Gimeno, Paul Coppo
Journal: Blood (2009)
Recent Decrease in Acute GVHD and Increased Relapse in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants.
Authors: Stella M. Davies, D. Wang, T. Wang, M. Arora, O. Ringden, C. Anasetti, S. Pavletic, J. Casper, M.L. MacMillan, J. Sanders, D. Wall, N.A. Kernan
Journal: Blood (2007)
Addition of Oblimersen (Bcl-2 Antisense) to Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic Lymphocytic Leukemia Extends Survival in Patients Who Achieve CR/nPR: Results from a Randomized Phase 3 Study.
Authors: Susan O’Brien, Joseph Moore, Lily Ding, Steven Novick, Kanti Rai
Journal: Blood (2007)
Risk factors for nonpurulent leg cellulitis: a systematic review and meta-analysis
Authors: M. Quirke, F. Ayoub, A. McCabe, F. Boland, B. Smith, R. O'Sullivan, A. Wakai
Journal: British Journal of Dermatology (2016)

Nonpurulent cellulitis is an acute bacterial infection of the dermal and subdermal tissues that is not associated with purulent drainage, discharge or abscess. The objectives of this systematic review and meta‐analysis were to identify and appraise all controlled observational studies that have examined risk factors for the development of nonpurulent cellulitis of the leg (NPLC). A systematic literature search of electronic databases and grey literature sources was performed in July 2015. The Newcastle–Ottawa Scale (NOS) was used to assess methodological quality of included studies. Of 3059 potentially eligible studies retrieved and screened, six case–control studies were included. An increased risk of developing NPLC was associated with previous cellulitis [odds ratio (OR) 40·3, 95% confidence interval (CI) 22·6–72·0], wound (OR 19·1, 95% CI 9·1–40·0), current leg ulcers (OR 13·7, 95% CI 7·9–23·6), lymphoedema/chronic leg oedema (OR 6·8, 95% CI 3·5–13·3), excoriating skin diseases (OR 4·4, 95% CI 2·7–7·1), tinea pedis (OR 3·2, 95% CI 1·9–5·3) and body mass index > 30 kg m−2 (OR 2·4, 95% CI 1·4–4·0). Diabetes, smoking and alcohol consumption were not associated with NPLC. Although diabetics may have been underrepresented in the included studies, local risk factors appear to play a more significant role in the development of NPLC than do systemic risk factors. Clinicians should consider the treatment of modifiable risk factors including leg oedema, wounds, ulcers, areas of skin breakdown and toe‐web intertrigo while administering antibiotic treatment for NPLC.
THU0147 Drug Survival of Golimumab in Japanese Patients with Rheumatoid Arthritis Is Independent of Methotrexate and Prednisolone Concomitance: Results from The Multicenter Biologics Registry: Table 1.
Authors: M. Hayashi, T. Kanamono, H. Matsubara, K. Kishimoto, N. Takahashi, T. Kojima, N. Ishiguro
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> When using biological agents, particularly tumor necrosis factor (TNF) inhibitors, in patients with rheumatoid arthritis (RA), the use of methotrexate (MTX) or prednisolone (PSL) can cause considerable problems for patients because they cause adverse events. Therefore, safety would be increased if MTX and PSL could be tapered or stopped. The objective of this report was to determine the drug retention rate of golimumab (GLM) in Japanese patients with RA and identify potential predictors associated with treatment discontinuation. <h3>Methods</h3> A prospective analysis was performed on 152 patients with RA who were treated with GLM in our multicenter biologics registry. We assessed the age, body weight, disease duration, use of pre-biological agents, Disease Activity Score 28-Erythrocyte Sedimentation Rate, and use and dose of MTX and PSL as baseline characteristics of the patients, and we compared cumulative survival among these factors. <h3>Results</h3> The overall 52 weeks drug survival rate of GLM was 71.6%. The patients with a body weight of &lt;50 kg had a better drug survival rate than those with a body weight of &gt;50kg (see Table). The use and dose of MTX and use of PSL did not show statistical differences in drug survival rate (see Table). <h3>Conclusions</h3> In daily practice, patients with RA taper or stop their MTX or PSL use while undergoing treatment with biological agents if their RA disease activities are low. On the other hand, MTX with biological agents, particularly TNF inhibitors, would produce better efficacy than higher dose. Our result indicates that Japanese patients with RA receiving GLM may be able to taper or stop MTX and PSL use, which could increase safety and raise the drug retention rate in these patients. These data would be of value in selecting biological agents for MTX-intolerant RA patients. <h3>Disclosure of Interest</h3> None declared
The Effect of Telomerase Antisense for the Differentiation of Embryonic Stem Cells to Hemopoietic Stem Cells.
Authors: Kyong Hwa Park, Byung Soo Kim, In Keun Choi, Seok Jin Kim, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
Journal: Blood (2004)
In Vitro Activity of a Novel Fully Human Anti-CD40 Antibody CHIR-12.12 in Chronic Lymphocytic Leukemia: Blockade of CD40 Activation and Induction of ADCC.
Authors: Xia Tong, Georgios V. Georgakis, Long Li, O’Brien Susan, Younes Anas, Luqman Mohammad
Journal: Blood (2004)
Genetic Correction of Sickle Cell Disease by Co-Regulated γ-Globin Transgene Expression and ßS Interference.
Authors: Selda Samakoglu, Yelena Usachenko, Tulin Budak-Alpdogan, Santina Acuto, Rosalba DiMarzo, Aurelio Maggio, John Tisdale, Isabelle Riviere, Michel Sadelain
Journal: Blood (2005)
FRI0531 Differences in Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According To Different Remission Criteria
Authors: G. Ozen, A.U. Unal, A. Topcu, P. Atagunduz, H. Direskeneli, N. Inanc
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> At the present time remission is the target for treatment of rheumatoid arthritis (RA). Various composite indices are available that can be used to define remission. Although the new ACR/EULAR Boolean criteria is more stringent than others, it is difficult to achieve and even more difficult to sustain this Boolean remission. <h3>Objectives</h3> In this study we aimed to determine the differences of the ultrasonographically (US) assessed actual disease activities of the patients in remission according to different remission criteria. <h3>Methods</h3> RA patients in clinical remission (DAS28-ESR&lt;2.6) for at least 3 months were included to this cross-sectional study. All patients9 remission status according to DAS28-ESR-3, DAS28-CRP, SDAI, CDAI and Boolean based definitions were assessed. A standard gray scale (GS) and power Doppler (PD) US examination of 28 joints (included in DAS28) for the presence of synovitis was performed by an experienced sonographer (NI) blinded to clinical data. US synovitis GS and PD signals were semiquantitatively graded from 0 to 3. Total PD and GS synovitis scores of all sites are recorded as sum scores of PD and GS, respectively. <h3>Results</h3> A total of 88 out of 389 RA patients (22.6%) in DAS28 remission were enrolled (F/M=55/33, mean age 53.4±12.0, disease duration 10.5±6.3 years, bDMARDs 44.3%, RF/Anti-CCP positivity 72%). Of the 88 patients, 82 (93.2%), 72 (81.8%), 49 (55.7%), 40 (45.5%) and 33 (37.5%) fulfilled the DAS28-CRP, DAS28-ESR-3, SDAI, CDAI and Boolean remission criteria, respectively. PD synovitis scores which have shown to be associated with erosion development and worse functional outcome were lowest in CDAI, Boolean and SDAI remission. However despite that, those differences in US disease activity parameters (both PD and GS synovitis sum scores and percentages of patients without PD and GS signals [with both omitting and including grade 1 signals]) in remission patients according to different criteria were not statistically significant (<i>Table 1</i>). In comparison of US disease activity parameters of remission vs nonremission groups, only patients with Boolean and CDAI remission had significantly lower PD scores compared to their counterpart nonremission group (for both, 1 [0–4] vs 3 [1–7], <i>P</i>=0.015). <h3>Conclusions</h3> US verified joint inflammation is the lowest in RA patients who are in remission according to Boolean and CDAI criteria. However, the clinical significance of this statistically nonsignificant inflammatory activity compared to other clinical remission criteria should be assessed in prospective studies. Till then, in clinical practice if Boolean remission could not be achieved, CDAI or SDAI could also be preferred as the remission target. <h3>Disclosure of Interest</h3> None declared
Follow-Up of Chronic Lymphocytic Leukemia (CLL) Patients Who Relapse after Autologous Stem Cell Transplantation (ASCT).
Authors: Silvia M. Trisolini, Francesca R. Mauro, Saveria Capria, Giuseppe Cimino, Maria S. De Propris, Anna Proia, Robin Foà, Giovanna Meloni
Journal: Blood (2004)